Osteomyelitis
BASICS
Description
- Acute or chronic bone infection with associated inflammation
- Etiology: Hematogenous seeding, contiguous spread, or direct inoculation (trauma/surgery)
- Classification:
- Lew and Waldvogel: acute vs. chronic; hematogenous vs. contiguous
- Cierny-Mader: bone location, host status, risk factors
- Special situations:
- Vertebral osteomyelitis: usually hematogenous, lumbar most common; presents with back pain
- Prosthetic joint infections: x-ray, bone scan; MRI/CT less helpful due to artifact
- Posttraumatic: tibia most common site
EPIDEMIOLOGY
- More common in older adults; male > female
- Children: hematogenous, long bones
- Adults: vertebral (hematogenous), prosthetic, diabetic foot, trauma
- TB: most common vertebral cause worldwide; thoracic spine, paraspinal abscess
- Incidence: vertebral—2.4/100,000 (increases with age)
- Prevalence: up to 66% of diabetics with foot ulcers
ETIOLOGY & PATHOPHYSIOLOGY
- Acute: Suppurative infection → edema, vascular compromise, necrosis (sequestrum)
- Chronic: Necrotic bone, sequestrum, or recurrent infection
- Hematogenous: Monomicrobial (S. aureus most common; also coagulase-negative staph, gram-negative rods, Pseudomonas—IV drug use, Salmonella—sickle cell, TB/fungal—immunocompromised/endemic)
- Contiguous: Polymicrobial (staph, strep, gram-negatives, anaerobes); common in diabetes, vascular insufficiency, trauma
- Special situations: P. aeruginosa (puncture wound through shoe); prosthetic—coagulase-negative staph/S. aureus
RISK FACTORS
- Diabetes mellitus (esp. foot ulcer)
- Recent trauma or surgery
- Prosthetic implants/foreign body
- Neuropathy, vascular insufficiency
- Immunosuppression (dialysis, etc.)
- Sickle cell disease
- Injection drug use
- Prior osteomyelitis, bacteremia
GENERAL PREVENTION
- Annual foot exam for diabetics; manage peripheral artery disease, optimize glycemic control
- Antibiotic prophylaxis (perioperative for trauma/orthopedic surgery)
- Closed fractures: cefazolin, cefuroxime, or clindamycin/vancomycin (if allergy/MRSA)
- Open fractures: 1st-gen cephalosporin within 3h, ceftriaxone for type III, add metronidazole for gross contamination
DIAGNOSIS
History
- Acute: fever, chills, pain, swelling, erythema
- Chronic: draining sinus, history of prior infection, less systemic symptoms
- Vertebral: back pain, fever, restricted ROM, neuro deficits (in ⅓)
- Diabetics may have masked symptoms due to neuropathy/vascular disease
Physical Exam
- Fever, localized tenderness, swelling, redness, reduced ROM
- Motor/sensory loss (vertebral)
- Exposed bone in DFI
Differential Diagnosis
- Systemic infection, aseptic bone infarction, overlying skin/soft tissue infection (gout), Brodie abscess, Charcot joint, tumor
Diagnostic Tests
- Labs:
- WBC—may be normal
- CRP/ESR—usually elevated (ESR >70 increases likelihood >10-fold)
- Anemia (chronic)
- Blood cultures (esp. vertebral/hematogenous)
- Procalcitonin—may be elevated
- Imaging:
- X-ray (late findings: demineralization, periosteal reaction, destruction)
- Bone scan (esp. prosthesis)
- MRI—gold standard for spinal, DFI, and septic arthritis (sensitivity ~90%, specificity ~80%)
- CT—bone fragments/sequestra
- Procedures:
- Probe-to-bone test: high sensitivity/specificity in DFI
- Bone biopsy: definitive (culture/histology); avoid wound swabs in DFI
- Pathology: necrosis, pyogenic bacteria
TREATMENT
General Measures
- Nutrition, glycemic control, foot care, smoking/IV drug use cessation
Medication
- Delay empiric antibiotics if stable until after biopsy/culture
- Acute: 4–6 weeks antibiotics (longer for chronic/MRSA)
- Vertebral/hematogenous: 6 weeks
- Post-amputation/removal: 2 weeks may suffice if complete removal
- Empiric (tailor to cultures):
- MRSA/gram-negative coverage: IV vancomycin + 3rd/4th gen cephalosporin
- DFI/contiguous: add metronidazole for anaerobes
First Line
- MSSA: Nafcillin/oxacillin 2g IV q4h or cefazolin 1–2g IV q8h
- MRSA: Vancomycin 15–20 mg/kg IV q8–12h (target trough 15–20)
- Strep: Ceftriaxone 2g IV q24h or cefazolin 2g IV q8h
- Pseudomonas: Cefepime 2g IV q8h or ciprofloxacin 750 mg PO q12h
Second Line
- MSSA: Ceftriaxone 2g IV q24h
- MRSA: Linezolid 600 mg PO/IV q12h, daptomycin 6 mg/kg IV q24h
- Strep: Penicillin G 4 million U q4–6h
- Pseudomonas: Piperacillin-tazobactam 3.375g IV q6h
ALERT: Vancomycin + piperacillin-tazobactam ↑ risk of acute renal failure (NNH = 11).
Additional Therapies
- Hyperbaric oxygen therapy (chronic/refractory)
- Monitor: Weekly labs (antimicrobial levels, CRP, ESR)
Surgery/Procedures
- Surgical drainage, debridement to healthy bone, minimize dead space, restore blood supply, soft tissue coverage
- Hardware: Remove if possible; if retained, prolonged antibiotics
- Antibiotic cement beads: for dead space in vascular insufficiency
Admission/Inpatient
- Off-load pressure, monitor clinical/lab resolution before discharge
ONGOING CARE
- Follow-up: Monitor CRP/ESR, radiographs, antimicrobial levels as needed
DIET
- Glycemic control in diabetics, nutrition for malnourished
PATIENT EDUCATION
- Foot care in diabetics, IV drug use cessation
PROGNOSIS
- Acute/superficial/medullary: Cure in 90–100% with appropriate management
- Chronic/diabetics: Up to 36% recurrence; ↑ mortality after amputation
COMPLICATIONS
- Abscess, bacteremia, fracture, nonunion, prosthetic loosening, sinus tract (can → Marjolin ulcer), post-op infection
ICD-10 Codes
- M86.03: Acute hematogenous osteomyelitis, radius/ulna
- M86.032: ...left radius/ulna
- M86.01: ...shoulder
Clinical Pearls
- Hematogenous osteomyelitis: usually monomicrobial; contiguous/direct is usually polymicrobial
- Pain: typically gradual onset in acute cases
- Chronic osteomyelitis: requires debridement + ≥6 weeks antibiotics
- Probe-to-bone test: diagnostic in DFI; not diagnostic in stage IV sacral ulcers
- MRI: not for follow-up if clinical improvement
- No antibiotics for diabetic foot wounds without signs of infection